The announcement of new data showing the potential of Intercept Pharmaceuticals' fixed-dose combination treatment for Primary Biliary Cholangitis is likely to be seen as a positive development by investors. This could lead to increased interest in the company's stock and a potential rise in its stock price in the short term.